Drugs Made In America Acquisition Corp. Units (DMAAU) - Net Assets
Based on the latest financial reports, Drugs Made In America Acquisition Corp. Units (DMAAU) has net assets worth $232.64 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($239.92 Million) and total liabilities ($7.28 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Drugs Made In America Acquisition Corp. to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $232.64 Million |
| % of Total Assets | 96.97% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Drugs Made In America Acquisition Corp. Units - Net Assets Trend (2024–2025)
This chart illustrates how Drugs Made In America Acquisition Corp. Units's net assets have evolved over time, based on quarterly financial data. See Drugs Made In America Acquisition Corp. (DMAAU) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Drugs Made In America Acquisition Corp. Units (2024–2025)
The table below shows the annual net assets of Drugs Made In America Acquisition Corp. Units from 2024 to 2025. For live valuation and market cap data, see how much is Drugs Made In America Acquisition Corp. worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $232.64 Million | +95014465.94% |
| 2024-12-31 | $-244.85 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Drugs Made In America Acquisition Corp. Units's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 726477400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $239.91 Million | 103.12% |
| Total Equity | $232.64 Million | 100.00% |
Drugs Made In America Acquisition Corp. Units Competitors by Market Cap
The table below lists competitors of Drugs Made In America Acquisition Corp. Units ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nanjing OLO Home Furnishing
SHG:603326
|
$308.72 Million |
|
DiaMedica Therapeutics Inc
NASDAQ:DMAC
|
$308.75 Million |
|
Zhejiang Giuseppe Garment Co Ltd
SHE:002687
|
$308.76 Million |
|
Edda Wind ASA
OL:EWIND
|
$308.89 Million |
|
Polaris Media
OL:POL
|
$308.58 Million |
|
Huizhong Instrumentation Co Ltd
SHE:300371
|
$308.58 Million |
|
Bukwang Pharm
KO:003000
|
$308.58 Million |
|
D. Boral Acquisition I Corp. Class A Ordinary Shares
NASDAQ:DBCA
|
$308.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Drugs Made In America Acquisition Corp. Units's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -244 to 232,642,675, a change of 232,642,919.
- Net income of 5,940,643 contributed positively to equity growth.
- New share issuances of 232,050,000 increased equity.
- Other factors decreased equity by 5,347,724.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $5.94 Million | +2.55% |
| Share Issuances | $232.05 Million | +99.75% |
| Other Changes | $-5.35 Million | -2.3% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Drugs Made In America Acquisition Corp. Units's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.96x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $0.00 | $10.61 | x |
| 2025-12-31 | $11.07 | $10.61 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Drugs Made In America Acquisition Corp. Units utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.03x
- Recent ROE (2.55%) is above the historical average (1.28%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-454.60 |
| 2025 | 2.55% | 0.00% | 0.00x | 1.03x | $-17.32 Million |
Industry Comparison
This section compares Drugs Made In America Acquisition Corp. Units's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $173,103,317
- Average return on equity (ROE) among peers: 3.45%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Drugs Made In America Acquisition Corp. Units (DMAAU) | $232.64 Million | 0.00% | 0.03x | $308.64 Million |
| Artius II Acquisition Inc. (AACB) | $-60.27K | 0.00% | 0.00x | $232.84 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $268.87 Million |
| Ares Acquisition Corporation II (AACT) | $502.67 Million | 0.00% | 0.05x | $587.05 Million |
| AA Mission Acquisition Corp. (AAM) | $534.70 Million | 21.49% | 3.04x | $420.70K |
| Altenergy Acquisition Corp (AEAE) | $-12.44 Million | 0.00% | 0.00x | $72.22 Million |
| Activate Energy Acquisition Corp. Class A Ordinary Share (AEAQ) | $223.53 Million | 0.00% | 0.04x | $236.21 Million |
| American Exceptionalism Acquisition Corp. A (AEXA) | $328.45 Million | 0.00% | 0.06x | $390.09 Million |
| Aimei Health Technology Co., Ltd Ordinary Share (AFJK) | $8.04 Million | 13.18% | 0.51x | $107.66 Million |
| Aifeex Nexus Acquisition Corporation (AIFE) | $86.16 Million | -0.10% | 0.01x | $91.13 Million |
| AI TRANSPORTATION ACQUISITION CORP Ordinary shares (AITR) | $60.04 Million | -0.06% | 0.02x | $86.22 Million |
About Drugs Made In America Acquisition Corp. Units
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.